Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in adverse events up to week 12 compared with placebo (high certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).